²»Í¬¼ÁÁ¿Ë¾¿âÆæÓȵ¥¿¹ÖÎÁÆÖС¢ÖضÈÇ¿Ö±ÐÔ¼¹ÖùÑ×ÁÆЧÓ밲ȫÐÔµÄMeta·ÖÎö(2)
KEYWORDS Secukinumab; Medium and severe ankylosing spondylitis; Therapeutic efficacy; Safety; Meta-analysisÇ¿Ö±ÐÔ¼¹ÖùÑ×(Ankylosing spondylitis£¬AS)ÊÇÒ»·NÂýÐÔÑ×Ö¢ÐÔ¼²²¡£¬Ö÷Òª±íÏÖΪÖÐÖá¹Ç÷ÀºÍ÷¾÷ĹؽڵIJ¡±ä£¬Í¬Ê±Ò²¿ÉÓ°ÏìÖÜΧ¹Ø½ÚÓë¹Ø½ÚÍâÆ÷¹Ùϵͳ[1-2]¡£ÖС¢ÖضÈASÏà¹ØµÄÑ×Ö¢ÐÔ±³Í´ºÍ½©Ó²»áµ¼Ö»úÌ幦ÄÜÐÔË𺦺ͻ¼ÕßÉú»îÖÊÁ¿½µµÍ[3]¡£Ç°ÆÚÁ÷Ðв¡Ñ§µ÷²é×ÊÁÏÏÔʾ£¬ASÔÚÎÒ¹úµÄ·¢²¡ÂÊԼΪ0.3%[4]¡£AS¶Ô»¼ÕßÔì³ÉÁ˾޴óµÄÐÄÀí¸ºµ££¬Ò²µ¼ÖÂÉç»áÀͶ¯ÄÜÁ¦µÄɥʧ£¬ÒѳÉΪ½ÏÑÏÖصĹ«¹²ÎÀÉúÎÊÌ⣬ÆÈÇÐÐèÒªÓÐЧÇÒ°²È«µÄÖÎÁÆ´ëÊ©À´¸ÄÉÆ»¼ÕߵĽ¡¿µÏà¹ØÉú»îÖÊÁ¿[5]¡£¸ù¾Ý¹ú¼Ê¼¹×µ¹Ø½ÚÑ×лáºÍÅ·ÖÞ¿¹·çʪÁªÃ˵ÄÍƼö£¬·ÇçÞÌåÀ࿹Ñ×Ò©(NSAIDs)ºÍ¼²²¡ÐÞÊÎÀ࿹·çʪҩ(DMARDs)ͨ³£×÷Ϊ´«Í³µÄÒ»ÏßÖÎÁÆÒ©Îï[6]¡£µ«ÊÇÕâЩ´«Í³Ò©Îï³£±»±¨µÀ²»ÄÜÓÐЧ¸ÄÉÆASÏà¹ØÖ¢×´[7-8]¡£ÓÐÑо¿ÏÔʾ ......
ÄúÏÖÔڲ鿴ÊÇÕªÒªÒ³£¬È«Îij¤ 4147 ×Ö·û¡£